Cellosaurus LAMA-84 (CVCL_0388)

Cell line name LAMA-84
Synonyms Lama-84; LAMA84; Lama84
Accession CVCL_0388
Resource Identification Initiative To cite this cell line use: LAMA-84 (RRID:CVCL_0388)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Doubling time: 36 hours (PubMed=25984343); ~50 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Peripheral blood.
Disease Chronic myelogenous leukemia, BCR-ABL1 positive (NCIt: C3174)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_1826 (LAMA-87); CVCL_9540 (LAMA-88); CVCL_DP57 (LAMA84-r); CVCL_DP54 (LAMA84-rn); CVCL_AE17 (LAMA84R)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): CLS; Cosmic-CLP; DSMZ

Markers:
AmelogeninX
CSF1PO11,12 (CLS; Cosmic-CLP)
8,11,12 (DSMZ)
D12S39118,24
D13S31711
D16S53911
D18S5113
D19S43313
D1S165615,15.3
D21S1129,30,31
D2S133817
D3S135814,17
D5S81811,12
D6S104310,20
D7S82011
D8S117910,15
FGA21,22
Penta D10
Penta E7
TH016,7
TPOX10
vWA14,17
Publications

PubMed=3476310
Seigneurin D., Champelovier P., Mouchiroud G., Berthier R., Leroux D., Prenant M., McGregor J., Starck J., Morle F., Micouin C., Pietrantuono A., Kolodie L.
Human chronic myeloid leukemic cell line with positive Philadelphia chromosome exhibits megakaryocytic and erythroid characteristics.
Exp. Hematol. 15:822-832(1987)

PubMed=8693292; DOI=10.1046/j.1365-3083.1996.d01-84.x
Blom T., Nilsson G., Sundstrom C., Nilsson K., Hellman L.
Characterization of a human basophil-like cell line (LAMA-84).
Scand. J. Immunol. 44:54-61(1996)

PubMed=15843827; DOI=10.1038/sj.leu.2403749
Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M., Fioretos T.
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Leukemia 19:1042-1050(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections CLS; 300261/p2498_Lama-84
DSMZ; ACC-168
Cell line databases/resources CLDB; cl3168
CCLE; LAMA84_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
Cosmic-CLP; 907783
GDSC; 907783
LINCS_LDP; LCL-1109
Lonza; 961
Ontologies BTO; BTO:0004465
CLO; CLO_0007238
MCCL; MCC:0000283
Biological sample resources BioSample; SAMN03473363
Chemistry resources ChEMBL-Cells; CHEMBL3308267
ChEMBL-Targets; CHEMBL2366090
Gene expression databases GEO; GSM887262
GEO; GSM888337
GEO; GSM1670031
Polymorphism and mutation databases Cosmic; 787500
Cosmic; 907783
Cosmic; 1012081
Cosmic; 1019834
Cosmic; 1026569
Cosmic; 1078729